75.39% of the stock is owned by institutional investors and hedge funds. Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell ...

Elicio Therapeutics ( (ELTX) ) has issued an announcement.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from ...

Initiating oseltamivir on the same day as hospital admission reduced the risk for severe clinical outcomes in adults ...

Hepatitis, an inflammation of the liver caused by viral infections or other factors, remains a significant global health ...

Updated Phase 1 data include a 16.3-month median recurrence-free survival (“mRFS”) and 28.9-month median overall survival (“mOS”) from full study ...

In the continuation of our discussion with Chris Sayed, MD, University of North Carolina at Chapel Hill Department of ...

The symptoms of Irritable Bowel Syndrome IBS and Inflammatory Bowel Disease IBD usually overlap however there’s a vast ...

Filgotinib, a JAK1 preferential inhibitor, shows promise as an effective and well-tolerated maintenance therapy for Crohn's ...

Detailed price information for Sonnet Biotherapeutics Holdings Inc (SONN-Q) from The Globe and Mail including charting and trades.